By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Purdue Pharma Products LP et al. v. Par Pharmaceutical Inc. et al.
1:07-cv-00666; filed October 24, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 6,254,887 ("Controlled Release Tramadol," issued July 3, 2001) following a paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of plaintiffs' Ultram® ER (tramadol hydrochloride, used to treat moderate to moderately severe chronic pain). View the complaint here. As reported here and here, plaintiffs have previously asserted this patent against Par Pharmaceutical; the present complaint includes an additional dosage included in Par's ANDA.
Alcon Manufacturing, Ltd et al. v. Barr Laboratories, Inc.
1:07-cv-01377; filed October 23, 2007 in the Southern District of Indiana
Infringement of U.S. Patent Nos. 5,641,805 ("Topical Ophthalmic Formulations for Treating Allergic Eye Diseases," issued June 24, 1997) and 5,116,863 ("Dibenz[b,e]oxepin Derivative and Pharmaceutical Compositions Thereof," issued May 26, 1992) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Alcon's Patanol® (an ophthalmic solution containing olopatadine hydrochloride, used to treat allergic conjunctivitis). View the complaint here.
Sciele Pharma Inc. et al. v. Mylan Pharmaceuticals Inc. et al.
1:07-cv-00664; filed October 22, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 4,892,741 ("Press coated DHP tablets," issued January 9, 1990) following a paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Sciele's Sular® (nisoldipine, used to treat hypertension). View the complaint here.
Schering Corporation v. Dr. Reddy's Laboratories, Inc. et al.
3:07-cv-05062; filed October 19, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 6,100,274 ("8-chloro-6,11-dihydro-11-] (4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine Oral Compositions," issued August 8, 2000) and 6,709,676 ("Extended Release Oral Dosage Composition," issued March 23, 2004) following a paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex-D® 12-hour (desloratidine and pseudoephedrine sulfate, used to treat allergies). View the complaint here.
Schering Corporation v. Dr. Reddy's Laboratories, Inc. et al.
3:07-cv-05038; filed October 19, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,100,274 ("8-chloro-6,11-dihydro-11- ] (4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine Oral Compositions," issued August 8, 2000) following a paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex (desloratidine, used to treat allergies). View the complaint here.
King Pharmaceuticals Inc. et al. v. Actavis, Inc. et al.
2:07-cv-05041; filed October 18, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,066,339 ("Oral Morphine Particulate Formulation," issued May 23, 2000) following a paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of King's Avinza® (morphine sulfate extended release capsules, used for the once-daily treatment of moderate-to-severe chronic pain). View the complaint here.
Sepracor Inc. et al. v. Mylan Pharmaceuticals, Inc. et al.
3:07-cv-05017; filed October 18, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007) and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007), licensed to Schering-Plough, following a paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex® (desloratidine, used to treat allergies). View the complaint here.
Comments